Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies

2022.03.31

Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-founder, Representative Director: Hiroki Danno, Masakazu Fukuda; hereinafter referred to as “Knowledge Palette”) announce that both companies have entered into a collaborative research contract for establishment of a new evaluation platform using Axcelead DDP’s compound libraries and Knowledge Palette’s large-scale transcriptome analysis technologies.

In this collaboration, whole gene expression data of cells treated with a wide variety of characteristic compounds, which are selected from the Axcelead DDP’s compound libraries, will be obtained using Knowledge Palette’s large-scale transcriptome analysis technologies. Both companies are aiming to analyze genes linked with various diseases or drug efficacy, safety, toxicity, etc. of the compounds and establish a new evaluation platform which can predict and reveal mechanisms of drug action, by combining the newly obtained data with metadata which Axceleadd DDP has stored.

Through the collaborative research, we will build an unique perturbative gene expression database by gene expression profiling of the cells treated with characteristic compounds. By utilizing the database, we can increase the effectiveness of target deconvolution in phenotypic drug screening, drug repositioning, lead generation and optimization, and toxicity prediction.

Yoshinori Ikeura, CEO of Axcelead DDP, says: “The collaborative research with Knowledge Palette allows us to establish a competitively advantageous, unique database from our compound libraries. By using the database, we will make more effective processes for drug discovery research and make a contribution as a hub for drug discovery ecosystem.”

Hiroki Danno, Representative Director and CEO of Knowledge Palette, says: ” We have an extensive phenotypic drug discovery platform based on whole gene expression profiling. By adding the integrated data from this collaborative research to the database of our platform, we will be able to explore and discover a variety of drug candidates with high success rate of development more effectively. “

About Axcelead Drug Discovery Partners, Inc.

Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded the drug discovery research capabilities of Takeda Pharmaceutical Company Limited and started its business on July 1, 2017. The company provides integrated services, from discovery of drug targets to optimization of small- and medium-molecule drug candidates, in which the company has particular expertise, and to the process of bridging the gap to clinical development. A-HiT Project is a library of potential drug candidates and optimized evaluation systems for a variety of drug targets.

About Knowledge Palette, Inc.
Knowledge Palette is a Japanese biotechnology company conducting phenotypic drug discovery, biomarkers identification, and improvement of regenerative medicine manufacturing based on our single cell transcriptome analysis technology (Quartz-Seq2), which was ranked No.1 for both accuracy scores and overall scores in an international benchmark project in 2020. We are collaborating with pharmaceutical companies and research institutes on acceleration of drug discovery as well as optimization of cell culturing for regenerative medicine.
https://www.knowledge-palette.com/en/